news
Increased operating profit in local currencies by 15% in the first quarter of 2014
1 May 2014 | By Novo Nordisk
7% sales growth in local currencies driven by Levemir® and Victoza®...
List view / Grid view
Novo Nordisk
news
Novo Nordisk invests 550 million Danish kroner in new purification pilot plant in Denmark
14 March 2014 | By Novo Nordisk
Novo Nordisk is increasing its drug development capacity by investing 550 million Danish kroner in a new research and development facility in Bagsværd, Denmark...
news
Election of employee representatives to the Board of Directors of Novo Nordisk A/S
27 February 2014 | By Novo Nordisk
The employees of Novo Nordisk A/S have conducted the election of employee representatives to the Board of Directors of Novo Nordisk A/S...
news
Novo Nordisk launches its shortest needle: NovoFine® Plus, compatible with all major pen devices
20 January 2014 | By Novo Nordisk
Canada is the first country to make NovoFine® Plus available and will be followed by several other countries during 2014 and 2015...
news
Novo Nordisk reported to the police by the Danish Financial Supervisory Authority for violating disclosure obligation
10 December 2013 | By Novo Nordisk
The reporting relates to the company’s receipt of a Complete Response Letter from the US Food and Drug Administration...
news
Ryzodeg® offers improved glycaemic control with significantly lower rates of hypoglycaemia compared to biphasic insulin aspart 30 in adults with type 2 diabetes
3 December 2013 | By Novo Nordisk
Data presented at the World Diabetes Congress of the International Diabetes Federation show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia...
news
IDegLira demonstrates superior glycaemic control and weight loss with a low rate of hypoglycaemia for patients uncontrolled on basal insulin
3 December 2013 | By Novo Nordisk
New phase 3 data from the investigational therapy IDegLira were presented at the World Diabetes Congress of the International Diabetes Federation...
news
Novo Nordisk and Roche Diabetes Care are joining forces to make insulin pump therapy simpler for people with diabetes
22 November 2013 | By Novo Nordisk
Insulin aspart PumpCart® is a 1.6 ml prefilled insulin pump cartridge containing the rapid-acting insulin aspart...
news
NovoEight® passed the review by the Committee on Drugs of Pharmaceutical Affairs in Japan
18 November 2013 | By Novo Nordisk
NovoEight® has passed the review by the Committee on Drugs of Japan's Pharmaceutical Affairs and Sanitation Council...
news
Novo Nordisk receives FDA approval for FlexTouch® in the US
1 November 2013 | By Novo Nordisk
FlexTouch® is the latest innovation in prefilled insulin delivery systems from Novo Nordisk...
news
Novo Nordisk increased operating profit by 10% in the first nine months of 2013
31 October 2013 | By Novo Nordisk
Sales growth of 8% driven by Victoza®, Levemir® og NovoRapid®...
news
Novoeight® (turoctocog alfa) receives approval from the FDA
16 October 2013 | By Novo Nordisk
“The approval of Novoeight® marks an important step in offering a new alternative for people with haemophilia A..."
news
IDegLira improves glycaemic control throughout the day with no weight gain and a low rate of hypoglycaemia
27 September 2013 | By Novo Nordisk
Data from the DUAL™ I trial show IDegLira demonstrates a statistically significant greater reduction in blood sugar levels (HbA1c) compared to insulin degludec or liraglutide alone...
news
Enrolment of Victoza® (liraglutide) cardiovascular outcomes trial completed on schedule
25 September 2013 | By Novo Nordisk
Recruitment for the LEADER® trial assessing cardiovascular (CV) outcomes of the once-daily GLP-1 analogue, Victoza®, completed in April 2012, resulted in a high-risk population with patient numbers exceeding the original target...
news
NovoEight® (turoctocog alfa) receives positive opinion from the European regulatory authorities
20 September 2013 | By Novo Nordisk
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion on its recombinant factor VIII product turoctocog alfa, with the intended brand name NovoEight®...
